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Measurement of plasma homocysteine may be of value in several clinical conditions including homocystinuria, atherosclerosis, thrombophilia, and folate/vitamin B 12 deficiency. The increasing interest in measuring total homocysteine in plasma has led to the development of several different methods [1] .
A widely used technique for measuring total plasma homocysteine is reversed-phase HPLC with fluorescence detection after derivatization of plasma thiols with ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBD-F) [2, 3] . Most published methods use external calibration alone for quantitation of homocysteine because of the difficulty in selecting an internal standard. We have modified this method by adding cysteamine hydrochloride as an internal standard to the plasma or homocysteine calibrator to compensate for variations in thiol derivatization and sample injection procedures.
HPLC was carried out by an isocratic system with fluorescence detection (SFM 25 spectrofluorometer), autosampler (SA 360), and HPLC pump (325) supplied by Kontron Instruments. Chemicals were obtained from Sigma. The method has been adapted from that of Ubbink et al. [2] on the basis of the chemical description provided by Araki and Sako [3] . The plasma or homocysteine calibrator (150 L) was incubated with 100 mL/L tri-nbutylphosphine in dimethylformamide (15 L) for 30 min at 4°C to reduce and release protein-bound thiols. Deproteinization was achieved by the addition of 100 g/L trichloroacetic acid (150 L) and centrifugation. An aliquot of the supernatant (50 L) was mixed with sodium hydroxide (10 L, 1.55 mol/L), borate buffer (125 L, 0.125 mol/L, pH 9.5, containing 4 mmol/L EDTA), and SBD-F (50 L, 1 g/L) and incubated for 60 min at 60°C. The SBD-F derivative from the supernatant (20-L aliquot) was eluted isocratically from the Spherisorb ODS2 [4.6 mm (i.d.), 5-m particles] analytical column (Jones Chromatography). The mobile phase was 0.1 mol/L KH 2 PO 4 , pH 2.0, containing 40 mL/L acetonitrile at a flow rate of 0.8 mL/min.
Homocysteine calibrators (dl form) were prepared in the following matrices: deionized water, pooled plasma (anticoagulated with EDTA), phosphate buffer (0.1 mol/L, adjusted to pH 9.5), and borate buffers (0.1 mol/L, pH 9.5, with and without 2 mmol/L EDTA).
Cysteamine hydrochloride (2-mercaptoethylamine) was used as an internal standard, which was added to the plasma or homocysteine calibrator to achieve a final concentration of 10.0 mol/L (30 L of 50.0 mol/L cysteamine plus 120-L sample).
Plasma samples from healthy adults (volunteer blood donors) were obtained from whole blood collected into evacuated EDTA tubes (Vacutainer Tubes, Becton Dickinson) and cooled on ice, and the plasma was separated by centrifugation within 60 min of venipuncture. Plasma was stored for a maximum of 3 months at Ϫ70°C before assay. This sampling was approved by the Hospital Ethical Committee.
Chromatography of a plasma sample with added cysteamine produced five peaks (see Fig. 1 ) that were identified as cysteine, cysteamine, cysteinyl glycine, homocysteine, and glutathione by comparison of retention times with those of pure compounds run separately and confirmed by coelution when plasma was supplemented with these compounds. In the absence of cysteamine no peak appears at that position for plasma samples.
The mean recovery of homocysteine dissolved in water added to plasma to final concentrations of 2.5-40.0 mol/L was 101.2% (n ϭ 8; range ϭ 98.3-106.3%). In the presence of cysteamine, the mean recovery of added homocysteine to plasma to final concentrations of 2.0 -16.0 mol/L was 100.3% (n ϭ 10; range ϭ 88.8 -105.5%).
The response of the fluorometric detector was linear for homocysteine calibrators from 0 to 50.0 mol/L for all matrices used. When homocysteine was diluted with either water or pooled plasma, no difference in the calibration slopes was obtained. However, homocysteine calibrators in other matrices resulted in different calibration slopes (Fig. 2, top) in the following order, starting with the largest peaks: water ϭ pooled plasma Ͼ phosphate buffer (0.1 mol/L, pH 9.5) Ͼ borate buffer (0.1 mol/L, pH 9.5) Ͼ borate buffer (0.1 mol/L, pH 9.5, containing 2 mmol/L EDTA).
The calibration slopes for homocysteine diluted in different matrices were indistinguishable from each other when cysteamine was included as an internal standard 
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The within-batch imprecision (CV) with and without internal standards for low control plasma (7.8 mol/L) was 2.8% (n ϭ 10) and 8.3% (n ϭ 10), respectively, and for high control plasma (23.6 mol/L) was 2.2% (n ϭ 10) and 5.3% (n ϭ 10), respectively. The between-batch CVs of the assay with and without internal standards for low control plasma were 6.9% (n ϭ 75) and 11.0% (n ϭ 142), respectively, and for high control plasma were 7.9% (n ϭ 75) and 11.3% (n ϭ 125), respectively.
The distribution of homocysteine concentrations of plasma from healthy adult blood donors was nongaussian with a moderate skew towards higher values. In men (n ϭ 295, mean age 38.4 years, range 20 -69 years), the median plasma homocysteine was 8.5 mol/L with reference range 5.3-16.9 mol/L (2.5 and 97.5 percentiles). In women (n ϭ 348, mean age 34.3 years, range 19 -64 years), the median plasma homocysteine was 7.2 mol/L with reference range 4.5-13.9 mol/L.
This SBD-F method for homocysteine estimation gives chromatograms with well-defined peaks and stable baselines. The addition of cysteamine has considerably improved the within-and between-assay precision. Homocysteine and cysteamine derivatives behave in a predictable way in the assay both in water and plasma, in that the response of the fluorometric detector is linear for both compounds up to at least 50 mol/L.
External homocysteine calibration is markedly matrixdependent. The use of different buffers and the presence of EDTA has an overall effect on the thiol derivatization and its detection. Because total plasma homocysteine values were obtained from interpolation on the calibration curve, spuriously low calibrators result in falsely high homocysteine values. Few details have been given in published methods for homocysteine assays as to how the homocysteine calibrators were constituted [1] [2] [3] [4] [5] [6] . In the original HPLC SBD-F-based method of Araki and Sako [3] , homocysteine calibrators were dissolved in borate buffer (0.1 mol/L, pH 9.5, containing 2 mmol/L Na 2 EDTA). In the method of Ubbink et al. [2] , based on the same principle, water is used instead of borate buffer [J. B. Ubbink, personal communication]. Vester and Rasmussen [4] reported that the calibration slopes of homocysteine calibrators diluted in borate buffer (0.1 mol/L, pH 9.5, containing 2 mmol/L EDTA) were 15% less than in the pooled plasma calibration, which is similar to the effect reported here. They suggested that the differences could result from the presence of proteins, ionic strength, or other species affecting the derivatization step, and recommended plasma-based calibrators. Because the data reported here show no differences in the calibration slopes between water and pooled plasma, it is simpler and equally effective to dilute homocysteine calibrators in water.
The use of cysteamine as an internal standard was originally suggested by te Poele-Pothoff et al. [5] but has not been fully characterized for this purpose. HPLC assays for homocysteine incorporating mercaptopropionylglycine and N-acetylcysteine as internal standards have also been described [4, 6] . Unlike cysteamine, these compounds elute later than the homocysteine peak, which prolongs the run time. Cysteamine (NH 2 -CH 2 -CH 2 -SH) has sufficient chemical similarities to homocysteine to make it suitable as an internal standard. The concentration of naturally occurring cysteamine in human plasma as reported by previous workers is extremely low (Ͻ0.1 mol/L) [7] . This is confirmed by the failure to detect a peak at the cysteamine position in the experiments reported here when the internal standard is omitted from the reaction. The negligible concentration of naturally occurring cysteamine is therefore unlikely to interfere with cysteamine as an internal standard at a concentration of 10.0 mol/L.
Results of the recovery study have shown that cysteamine does not affect the behavior of homocysteine present in either plasma or aqueous matrices. The addition of cysteamine also compensates for the matrix dependency of external homocysteine calibration. This indicates that whatever the reason for variation in peak areas of homocysteine because of different matrices, this effect also operates for cysteamine and thus is compensated for when the results are calculated as ratios of peak area. Use of an internal standard can also compensate for variation in other aspects of the assay such as minor differences in sample injector volume or detector sensitivity. Several advantages are associated with inclusion of an internal standard, which is reflected in the improved precision achieved.
This work is funded in part by a project grant from the British Heart Foundation. Part of this work has been published in abstract form (J Inherit Metab Dis 1996; 19(Suppl 1):28).
Reaction of malondialdehyde (MDA) with thiobarbituric acid (TBA) or its diethyl derivative has been applied widely to assess lipid peroxidation in biological material [1] . The reaction yields a red MDA-TBA adduct, the product of 2 mol of TBA plus 1 mol of MDA [2] . The colored complex can be quantified spectrophotometrically from its visible absorbance ( max 532 nm) [3, 4] or by spectrofluorometry (exc 532 nm, em 553 nm) [5, 6] and is readily extractable into organic solvents such as butanol [7] . Preanalytical factors aside [8 -10] , interfering chromogens include several other ordinary side-products of lipid autooxidation, alkanals, alkenals, and alkadienals as well as bile pigments, cyclic peroxides, carbohydrates, and amino acids [11] [12] [13] [14] [15] [16] [17] [18] .
Isolation and quantification of the MDA-TBA adduct by HPLC reportedly largely eliminates the interfering chromogens [19, 20] . HPLC methods generally yield lower values than those based on direct measurements, and this would seem to reinforce their specificity. However, mean reference values for lipoperoxide concentrations in plasma of healthy adults (0.60 Ϯ 0.13 mol/L; n ϭ 41) were found by Wong et al. [21] , who used a specific HPLC method, to be consistent with those of Francesco et al. [22] (0.61 Ϯ 0.11 mol/L; n ϭ 20), without chromatographic separation. Similarly, Fukunaga et al. [23] reported but failed to explain a close correlation (r ϭ 0.972, n ϭ 14) between their specific HPLC assay (2.51 Ϯ 0.75 mol/L; MDA values taken from correlation plot) and the traditional direct Yagi method [5] (2.21 Ϯ 0.54 mol/L; similarly calculated). In a discipline where published reference values can vary 100-fold [24] , these examples represent remarkable concordance and question the ability of HPLC to reduce spectrophotometric interference to the MDA-TBA adduct.
Various approaches have been proposed to minimize analytical interference in direct methods without resorting to HPLC. These approaches include spectrophotometric correction formulas [24, 25] , derivative spectrophotometry [26] , and synchronous fluorescence [27] . By their strong correlation and close resemblance to values from HPLC methods [21, 28] , these direct assays are also shown to be as effective as HPLC in minimizing interference.
Why are HPLC methods in reality seemingly neither more discriminatory nor more valid than several traditional assays, despite almost unanimous claims to the contrary? HPLC methods are certainly less practical and less readily adapted to screening studies, and the red adduct stains the HPLC equipment, resulting in lengthy clean-up procedures. If no substantial advantages are offered, why adopt a more time-consuming and tedious technique? The answer for the lack of discrimination became apparent during trials to incorporate an internal standard, similarly derivatized by TBA, into the HPLC procedure. No published HPLC assay of the MDA-TBA chromogen has used an internal standard. Essential to selection of an internal standard was noncontribution from pseudo-MDA activity through coelution of an indistinguishable 532-nm-absorbing chromogen from the introduced internal standard.
Sucrose, fructose, other carbohydrates, several amino acids, and ascorbic acid, when exposed to hydroxyl radicals produced by ionizing radiation or metal-ion H 2 O 2 systems, yield products that give a genuine MDA-TBA adduct on heating with TBA [29] and were not considered as potential candidates. Various alkanals such as formaldehyde, acetaldehyde, propanal, and hexanal, which have been shown to both reduce MDA recovery and likewise coelute with the MDA-TBA adduct [12 and N.R. Badcock, G.D. Zoanetti, and E.S. Martin, personal observation] were not considered as potential candidates either. With the aforementioned precluded, we tested several other aldehydes, including 2-hexenal, cinnamic aldehyde, glyceraldehyde, furaldehyde, and 5-hydroxymethyl-2-furaldehyde, together with several compounds such as glycine-MDA, methionine-MDA, and dianil-MDA, which contain the MDA moiety [11] . All of these compounds reacted with TBA to form either yellow or red pigments with absorbance maxima at 450 or 532 nm, respectively. Importantly, all chromatograms indicated only two chromogens, the red, which always corresponded to the red MDA-TBA adduct irrespective of mobile phase Clinical Chemistry 43, No. 9, 1997 [8, 20, 21, 23, 30] , and the yellow reactive substance, which coeluted with a peak previously ascribed to an endogenous yellow TBA marker [30] . No other peaks were observed. In other words, despite HPLC, chromatographic separation of other red adducts from MDA-TBA could not be achieved.
The failure of HPLC to discriminate should not be totally unexpected. Examination of the majority of illustrative chromatograms generated from HPLC separation on C 18 columns of the MDA-TBA adduct [8, 21, 23, 30 -32] indicates a remarkable absence of those additional peaks that would be expected if HPLC separated the chromophore of interest from other interfering chromogens. The occasional exception to this clean HPLC single-peak elution profile is the yellow chromophore that elutes well before the MDA-TBA complex and has an absorbance maximum at 450 nm, and as such, is also well differentiated in the visible spectrum. Interestingly, Marcuse and Johansson [13] also reported the formation of only two pigments, a red one with a maximum absorbance at ϳ530 nm and a yellow one with maximum at 450 nm.
With a reason for the clean tracings on HPLC came the explanation for their demonstrated equivalence with various direct methods, particularly those that exploit a correction for nonspecific background absorbance. However, although a correction factor is about equally effective in minimizing artifacts, we considered another approach to reducing analytical interference that did not assume linearity of background absorption. This involved the back-extraction of the acidic chromophores from the n-butanol organic phase (an end-point of most MDA-TBA extraction methods, including the one that we adopted, that of Lepage et al. [8] ) into 200 L of 4 mol/L NaOH. Tetraethoxypropane (always Ͻ20 L) was added to plasma before reaction, in variance to published procedures, as an internal standard to eliminate bias in the assay from losses of any potential aldehyde trapped in protein as a Schiff base, coprecipitated, or absorbed onto any residual protein, and appropriate blanks were run in parallel to compensate for aldehydes present in solvents.
The back-extraction offered several advantages. The red MDA-TBA adduct was recovered completely by the NaOH extraction (99.5% Ϯ 1.7%) for an overall extraction efficiency of Ͼ95%. Especially in samples of low MDA content, the cleanup and concentrating step improved analytical detection limits severalfold without resorting to time-consuming evaporation. In fact, the detection limit, determined as described by Gatautis and Pearson [33] , was 0.3 mol/L and near that of chromatographic methods with fluorescence detection. A bathochromic shift of 14 nm occurred with sodium hydroxide, giving a peak maximum at 546 nm for the red chromophore. This was noteworthy for two main reasons. Icteric plasma (containing bilirubin or biliverdin) had TBA reactivity with the resulting chromophore, having maximum absorptivity at 560 nm in acid solution and 600 nm in alkaline solution. In other words, any potential interfering chromogen from this source was removed further from the MDA-TBA chromophore, resulting in minimal background absorbance at 546 nm. Secondly, the alkaline extract exerted a marked hypochromic effect on the yellow chromogen, again minimizing interference without the need to include a correction factor. By adjusting the pH between 2.5 and 4.5 and heating the MDA-TBA mixture at 100°C for 60 min, as recommended by Lepage et al. [8] , the pyrolysis products of carbohydrates (sucrose, fructose, lactose), amino acids (l-tyrosine, l-methionine, l-tryptophan), and ascorbic acid at 100 mol/L each were found not to interfere.
Because pyrimidine solutions in alkali are often unstable because of ring-opening, stability of the red complex in the 4 mol/L NaOH extract was examined. After 10 min, there was no change in absorbance; thereafter absorbance decreased linearly with a half-life of 21 h. Correlation based on a least-squares linear regression between our nonseparative method and reversed-phase HPLC (Lepage et al. [8] ), with the alkaline MDA-TBA adduct neutralized within 10 min of back-extraction for subsequent injection, gave a line of best fit with a slope of 0.8538 and a y-intercept of 0.116 mol/L (Fig. 1 ). The correlation coefficient was 0.978 (P Ͻ0.001), and the mean of the 39 samples obtained from healthy adults (12 women and 12 men, mean age 36 years, range 22-52 years) and porphyric patients (6 female and 9 male, mean age 33 years, range 8 -50 years) was 1.61 Ϯ 1.06 mol/L by our method and 1.51 Ϯ 0.93 mol/L by HPLC. Plasma MDA in healthy adult subjects averaged 0.89 Ϯ 0.29 mol/L by the direct assay and 0.88 Ϯ 0.29 mol/L by HPLC.
The method has been used to measure free radical generation in the cutaneous porphyrias both at diagnosis and in response to various treatment regimes. Porphyrins are photoactivated by ultraviolet light, causing tissue damage by release of free oxygen radicals, which manifests as photosensitivity [34 -36] . The resulting oxygenrelated free radicals have the potential to be especially cytotoxic in combination with the iron-induced oxidant stress of porphyria cutanea tarda (PCT) [37] [38] [39] . MDA 
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Technical Briefs was increased substantially in plasma drawn from these porphyric patients at diagnosis [3.04 Ϯ 0.30 and 2.29 Ϯ 0.26 mol/L for PCT and erythropoietic protoporphyria (EPP) patients, respectively, by direct assay], indicating oxygen-free radical inactivating capacity in these porphyrias ( Fig. 1 ). Specific therapies [34] , including chloroquine, ␤-carotene, charcoal, and cholestyramine, did not interfere. A detailed analysis of the concentrations and their relationship to plasma porphyrin amounts, photosensitivity, and other pathology will be reported elsewhere.
We conclude with the interesting and somewhat chastening observation that nonseparative methods that minimize background absorbance, either through correction factors, or, as in our case, back-extraction into NaOH, allow the MDA-TBA adduct to be measured with specificity comparable with HPLC methods.
This study was supported by a grant from the Australian Cystic Fibrosis Foundation. Apolipoprotein E (apo E) is a protein that plays an essential role in lipid metabolism and distribution [1] . The apo E gene is polymorphic, and its three alleles code for isoforms E2, E3, and E4, which differ by single-aminoClinical Chemistry 43, No. 9, 1997 acid substitutions [2] . The apo E3 allele is the predominant isoform in all populations studied. The apo E4 allele is associated with increased total serum cholesterol and greater odds for coronary heart disease [3] ; it also constitutes a major risk factor for Alzheimer disease [4] . The apo E2 allele seems to have a protective effect against Alzheimer disease and is associated with longevity [5] . Consequently, interest in examining individual patients and study groups for the apo E isoforms is growing. In this communication we describe a simple procedure that facilitates the genotyping of the apo E polymorphisms.
Improved Method for Genotyping Apolipoprotein E Polymorphisms by a PCR-Based Assay Simultaneously
In the common apo E3 polymorphism, TGC encodes for Cys 112 , and CGC encodes for Arg 158 . In the apo E2 another TGC codon results in Cys 158 , whereas in the apo E4 a different CGC codon gives rise to Arg 112 . The three apo E alleles determine six genotypes, i.e., three homozygotes designated E4/E4, E3/E3, and E2/E2 and three heterozygotes designated E3/E4, E2/E3, and E2/E4.
Early methods for detection of apo E isoforms were based on protein isoelectrofocusing [6] . After the identification of the apo E gene [7] molecular methods based on PCR amplification and HhaI digestion were introduced [8, 9] and later somewhat improved [10, 11] . However, all PCR-based assays are difficult to interpret because the HhaI enzyme yields several small fragments, not all of which are specific for the apo E genotypes. Moreover, incomplete digestion by HhaI can yield ambiguous results. In this study we used two new restriction enzymes, i.e., AflIII and HaeII, that recognize the allele-specific nucleotide substitutions at codons 112 and 158, respectively, and do not recognize additional sites. Fig.  1A illustrates schematically a loss of an AflIII restriction site that is characteristic for the apo E4 allele and a loss of an HaeII restriction site that is unique for the apo E2 allele (see asterisks).
DNA was purified from leukocytes by the salting-out method as described [12] . Genomic DNA was amplified by PCR with the primers F5Ј-TCCAAGGAGCTGCAG-GCGGCGCA and R5Ј-GCCCCGGCCTGGTACACT-GCCA to yield a 218-bp DNA fragment that spans both apo E polymorphic sites. In the PCR, 100 -200 ng of DNA was added to 25 L of reaction mixture containing 75 mmol/L Tris-HCl, pH 9.0, 20 mmol/L ammonium sulfate, 0.1 mL/L Tween, 1.5 mmol/L MgCl 2 , 500 nmol/L of each primer, 0.2 mmol/L dNTPs, 100 mL/L dimethyl sulfoxide, and 0.6 units of Taq polymerase (Advance Biotechnology).
The PCR reactions were subjected to 40 cycles in a thermal cycler (MJ Research) with 30 s of denaturing at 94°C, 30 s of annealing at 55°C, and 90 s of extension at 70°C. Amplified DNA (15 L) was digested simultaneously with 2.5 units of AflIII and 5 units of HaeII (New England Biologicals) for 24 h at 37°C, analyzed on 4% agarose gel (metaPhor, FMC), and visualized by ethidium bromide staining.
As expected, simultaneous digestion of the 218-bp amplified product yielded on 4% agarose gel electrophoresis 145-bp, 168-bp, and 195-bp fragments that were specific for apo E3, E2, and E4, respectively (Fig. 1) . All six possible genotypes for apo E, i.e., E2/E4, E4/E4, E3/E4, E3/E3, E2/E3, and E2/E2, were clearly discernible (lanes 2-7, respectively). In the E2/E4 genotype (Fig. 1B, lanes 2 and 8) a residual uncut 218-bp fragment was present. To characterize the nature of this uncut fragment, the following experiments were carried out. When the PCR product of the genotype E2/E2 was mixed with the PCR product of the genotype E4/E4 and subjected to simultaneous digestion with AflIII and HaeII, only the bands corresponding to alleles E2 (168 bp) and E4 (195 bp) were observed (Fig. 1B, lane 9) . In contrast, when the same mixture of E2/E2 plus E4/E4 was allowed to denature (95°C for 5 min) and anneal at 55°C before digestion, the uncut 218-bp band was observed (Fig. 1B, lane 10) . These findings were consistent with a heteroduplex formation between DNA strands carrying the E2 and the E4 sequences with its anticipated resistance to the enzyme digestion.
In conclusion, simultaneous digestion of an amplified segment of the apo E gene by AflIII and HaeII enzymes clearly determines all apo E genotypes. The assay is easy In A, the recognition sequences of these enzymes are depicted inside the boxes, and the vertical lines represent their cleavage sites. The bold letters T and C indicate the initiation of cysteine or arginine codons, respectively. The sizes (bp) of the digested fragments are shown between the arrows. Asterisks designate losses of restriction sites in the apo E2 and E4 alleles. In B, lane 1 depicts the 218-bp amplified segment, and lanes 2-7 show E2/E4, E4/E4, E3/E4, E3/E3, E2/E3, and E2/E2 genotypes, respectively. Lanes 8 -10 illustrate that the uncut 218-bp fragment is a E2/E4 heteroduplex (see text). The marker (M) HaeIIIdigested X174 was used as a standard. Benzodiazepines are used therapeutically as antidepressant, anxiolytic, anticonvulsant, hypnotic, muscle relaxant, and preanesthetic agents. Moreover, benzodiazepines are often abused for their euphoric effects. Consequently, benzodiazepines are commonly detected in toxicological analyses.
Immunoassays of benzodiazepines are plagued by several factors that make reliable detection difficult. Complicated metabolic pathways, including N-dealkylation, C-hydroxylation, and glucuronidation, effectively reduce the parent compound to more polar, and thus easily excreted, metabolites. Some of these metabolites are pharmacologically active; in some cases, they are present in higher concentrations and have a longer elimination halflife than the parent compound [1, 2] . Many, especially the glucuronide conjugates, which appear at high concentrations in the urine, do not readily cross-react with commercial immunoassays. In contrast, other benzodiazepine metabolites demonstrate high cross-reactivity, depending on the immunoassay utilized [3] .
In the US, 13 benzodiazepines of various potencies are commonly prescribed. Therapeutic daily doses have substantially decreased with the newer generation of benzodiazepines [2] . Variations in dosage and in ultimate excretion patterns complicate the ability to accurately detect benzodiazepine use [4] .
Accumulated research findings indicate pretreating urine specimens with ␤-glucuronidase (EC 3.2.1.31) increases the diagnostic sensitivity of benzodiazepine immunoassays. In addition, even untreated specimens with concentrations of benzodiazepine analytes below the cutoff concentration may screen positive because of the presence of highly cross-reactive benzodiazepine metabolites [3, 5] . Also, oxaprozin (Daypro ® ; G.D. Searle), a structurally unrelated nonsteroidal antiinflammatory drug, produces false-positive results in several commercial immunoassays [6 -8] .
In this study we evaluated whether automated on-line hydrolysis of benzodiazepine analytes would improve the sensitivity of the Boehringer Mannheim Corp. (BMC) cloned enzyme donor benzodiazepine immunoassay (CEDIA ® ). We evaluated in parallel 1002 urine specimens that were screened by two CEDIA benzodiazepine assays: the current assay with no enzymatic pretreatment, and a modified assay in which ␤-glucuronidase (200 U/mL; BMC) was added to the R1 reagent system (5 L of ␤-glucuronidase solution per milliliter of R1) for automated on-line hydrolysis of conjugated benzodiazepine analytes. (The modified CEDIA has also been evaluated recently by Bellet et al. [9] .) All specimens were analyzed with a Hitachi 717 (BMC) automated chemistry analyzer, with a positive cutoff concentration of 200 g/L (nitrazepam). All instrument settings were according to published manufacturer's guidelines for the CEDIA benzodiazepine assay.
All CEDIA presumptive positive specimens (n ϭ 50) were assayed by GC/MS. Before GC/MS analysis, the urine specimens were hydrolyzed with ␤-glucuronidase (Sigma Chemical Co.), followed by solid-phase extraction mass ions monitored at a dwell time of 20 ms. A multipoint calibration curve (25-500 g/L) and pentadeuterated internal standards (Radian Corp., Austin, TX) were used for quantification; i.e., quantification was based on the ion peak area ratio of the analyte to its corresponding pentadeuterated internal standard analog. The limit of quantification (LOQ) was established as 25 g/L. Analytes were identified on the basis of retention time (Ϯ1%) and ion ratios (Ϯ20%) by comparison with the corresponding values for the internal standards.
Manual pretreatment with enzyme before immunoassay analysis can be very time consuming. By using ␤-glucuronidase added to the R1 reagent of the CEDIA benzodiazepine assay and subsequent on-line incubation with the urine specimen, conjugated benzodiazepines were cleaved to yield more immunoreactive analytes. Compared with the current CEDIA, the modified CEDIA demonstrated a 26% increase in the number of presumptive positive results, from 37 to 50 specimens. Furthermore, all benzodiazepine-positive specimens demonstrated an increase in ⌬ absorbance rates (mA/min) with the modified assay, the increase ranging from 10 to 269 (mean, 72.56; SD, 70.19).
Results of the GC/MS analyses for the specimens that were negative by the current CEDIA, but positive by the modified CEDIA, are listed in Table 1 . The data demonstrate that ␤-glucuronidase pretreatment improves immunoassay detection of several benzodiazepine analytes, even at concentrations less than the cutoff calibrator. Benzodiazepine analytes for which detection was improved include lorazepam, nordiazepam, oxazepam, and temazepam. Of the 50 total specimens, 3 could not be confirmed by the chosen GC/MS assays and were subsequently submitted to BMC for analysis by alternative GC/MS methods. Two of these specimens were found to be positive for oxaprozin, and one was positive for alprazolam. Combining these GC/MS results with the CEDIA screening results gives a specificity of 99.8% for the current and modified CEDIA methods.
Our study shows that addition of ␤-glucuronidase to the R1 reagent of the CEDIA DAU benzodiazepine assay increases the detection of benzodiazepine analytes in urine specimens. To confirm the presence of benzodiazepine analytes in urine, a technique should be able to detect concentrations less than the immunoassay cutoff value. This sensitive on-line hydrolysis method provides a rapid and efficient urine screen for the presence of benzodiazepines.
This study was funded in part by Boehringer Mannheim Corp. [11, 12] , was used as a model for investigating the feasibility of CGE/LIF analysis of Cy-5-labeled PCR product and its restriction fragments. A P/ACE 5500 CE equipped with a 2.5 mW diode laser emitting at 652 nm and a LIF detector (Beckman Instruments) was used for the CE runs. Capillary columns, typically of 27 cm length (20 cm to detector window) ϫ 50 m i.d., were assembled in the P/ACE cartridge format. The columns were silaned with ␥-methacrylopropyltrimethoxysilane (Sigma) for 2 h and coated with 2% polyacrylamide for 1 h as described by Figeys et. al [4] . The cathode was set on the injection side. Before each separation step, the coated column was filled with replaceable gel buffer Clinical Chemistry 43, No. 9, 1997 ers were synthesized with a hexylamino terminus at its 5Ј end by Applied Biosystems. Both 5Ј-amino-linked forward and reverse primers (30 nmol each) dissolved in 300 L of 100 mmol/L Na 2 CO 3 (pH 9.5) were added to the Cy-5 dye vial from Amersham and allowed to stand at room temperature for 60 min. Fifty microliters of the conjugation mixture was loaded on a G-25 spin column and centrifuged at 1000g for 1 min to obtain purified Cy-5-labeled primer. All the conjugation and purification steps were monitored by CGE/LIF. The samples were hydrodynamically injected for 2 s under low pressure [3.45 kPa (0.5 psi)]. As demonstrated in Fig. 1A , in the conjugation mixture, the Cy-5-labeled primers migrate in front of Cy-5 diacid, which is a hydrolyzed product of Cy-5 in an alkaline condition [10] . After G-25 spin column purification, Cy-5 diacid was almost completely absorbed, while the labeled primer was all spun down without a decrease of concentration (Fig. 1B) . Less than one microliter of the purified, labeled primer mixture was enough for a PCR reaction.
Analysis of Cyanine
MELAS disease has been characterized by a major point mutation (A to G at 3243) in mitochondrial DNA. An ApaI restriction digestion site is generated at the site of mutation [12] . Muscle DNA extracted from a MELAS patient with Puregene DNA purification kit (Gentra) was used as a positive control. The sequence encompassing the MELAS mutation site was PCR-amplified with the Cy-5-labeled primer mixture according to the conditions described by Goto et al. [12] to generate a 739-bp PCR product. The MELAS-specific PCR product can be digested by ApaI into 211-and 528-bp restriction fragments. The size of the DNA fragments were verified by 2% agarose gel electrophoresis with X174 as the size marker (data not shown). For CGE/LIF analysis, the undiluted PCR-amplified mixture was hydrodynamically injected for 60 s with a prior injection of 0.1 mol/L Tris acetate (pH 8.3), which may improve peak resolution as described by Van der Schan et al. [13] . As demonstrated in Fig. 1C , the PCR product was detected at 7.2 min. After ApaI digestion, the two restriction fragments appeared at 5.7 min and 6.9 min and were well separated from the undigested PCR product (Fig. 1D) . The relative migration times (RMTs) of the PCR product and its restriction fragments with respect to the fastest moving primer (as indicated in the parentheses) are highly reproducible. The intraday and interday precisions for the RMT of each peak, expressed as CV (n ϭ 5), were Ͻ0.08% and 0.12%, respectively.
The concentrations of the PCR products were determined by the peak heights expressed as relative fluorescence units (RFUs) on the CGE/LIF electropherogram based on the calibration factor generated from serial dilutions of the PCR product with known concentration determined by a DNA concentrator (DyNA Quant 200 from Hoefer). To do this, MELAS PCR mixture with no excess primer was obtained by performing 45 thermal cycles. Serial 10-fold dilutions of such pure MELAS PCR product were analyzed by CGE/LIF. The peak height of each fragment was plotted against the concentration of the PCR product over the range of 5 ng/L to 50 g/L, within which a linear relation was obtained (data not shown). As each PCR product contains two Cy-5 molecules (conjugated with the forward and reverse primers), the fluorescence intensity of the Cy-5-labeled PCR product is in proportion to its molar concentration. The limit of detection of the 739-bp PCR product was ϳ3 ng/L (equal to 500 fmol/L) determined at 4:1 signal-to-noise ratio.
CGE/LIF detection of fluorescent PCR product derived from Cy-5-labeld primer is highly specific and reproducible. Apart from its application in the area of molecular diagnosis, this methodology has great potential in many areas such as gene expression and gene mutation studies. Osteocalcin (Oc) is a 49-amino-acid noncollagenous protein synthesized by osteoblasts. Because of the presence of three ␥-carboxyglutamic acid (GLA) residues, newly synthesized Oc will be primarily bound to hydroxyapatite present in bone matrix, only a small fraction being released into the circulation [1] . Although serum Oc concentration is considered a valid marker of bone turnover in most situations [2] , it reflects specifically bone formation when resorption and formation are uncoupled as observed in corticoid-induced osteoporosis [3] . Several reports have stressed recently that absolute Oc concentrations obtained with various in-house [4] or commercial [5] assays cannot be compared directly. An important cause for the discrepancies between Oc assays is the variabily of the anti-Oc antibody specificity for the circulating Oc fragments described by Garnero et al. [6] . The intact Oc molecule (1-49 Oc) is highly susceptible to tryptic proteolysis because of the presence of 2 Arg-Arg sites in positions 19 -20 and 43-44 [7] . When serum samples are not rapidly frozen, 1-49 Oc will be degraded quickly, the largest degradation product being a big N-terminal midfragment (1-43 Oc). This fragment is accumulated in patients with chronic renal failure (CRF) [6] . This problem of degradation is a major drawback in terms of specificity with an Oc assay that recognizes only 1-49 Oc. On the contrary, an Oc assay recognizing both 1-49 Oc and 1-43 Oc with equal affinity will be less sensitive to the effect of proteolysis [8] but of very limited value in CRF patients, as even those with adynamic bone disease will appear to have high serum Oc concentrations [9] . Antibody specificity is thus an important variable to be taken into account when interpreting serum Oc concentrations obtained with a given commercially available assay.
Simple Method to Evaluate Specificity of Osteocalcin
The objective of the present study was to assess the specificity of five commercial Oc assays (two RIAs, three IRMAs-listing and characteristics in Table 1 ). The evaluation was based on the use of two well-characterized IRMAs as reference reagents. Both reference IRMAs share a same standard preparation of highly purified human Oc and a same radiolabeled monoclonal antibody (MAb) directed against a sequence of the N-terminal region of the Oc molecule (5-13 Oc). The first of these two IRMAs (ELSA Ostnat; CIS bio) involves an anti-43-49 Oc MAb that is coated, and has thus an exclusive specificity for 1-49 Oc. The second IRMA (ELSA Osteo; CIS bio) previously described by Garnero et al. [10] involves an anti-25-37 Oc MAb as the capture antibody and thus recognizes both intact Oc and N-terminal mid-Oc equally.
To check the specificity of a given kit, our approach was to remove the molecular forms of Oc containing the C-terminal (43-49) region, including 1-49 Oc, from a serum specimen and then measure the residual immunoreactivity in the depleted sample with the kits to be tested. Fifteen sera from osteoporotic patients (OP; n ϭ 7) and CRF patients undergoing hemodialysis three times a week (HD; n ϭ 8) were incubated (0.25 mL) on a shaker (180 rpm) for 2 h at room temperature with the anti-43-49 Oc MAb (coated tubes from the ELSA Ostnat kit). Incubation was performed in duplicate for each serum and the two supernatants were pooled. During incubation, the native sera were handled in parallel and kept at room temperature to avoid differences in Oc molecule proteolysis between depleted and native sera. We then measured Oc in duplicate in both depleted and native sera by ELSA Ostnat, ELSA Osteo, and one of the assays to be tested. Because of potentially very high circulating Oc concentrations, native sera (but not depleted sera) from HD patients were first diluted to 1:3 in the zero calibrators from each kit. Thus, five experiments were performed, corresponding to each kit in evaluation. As the evaluations were spread over a period of time when kits to be tested were made available, these five groups of 15 sera were different and thus absolute concentrations cannot be compared The five experiments gave remarkably similar results. Patients were identified by a code to respect confidentiality. The validity of our method was assessed by the following findings: (a) Oc measured by ELSA Ostnat in depleted sera was below the detection limit of the assay in all specimens from OP patients and in most samples from HD patients, suggesting that 1-49 Oc was efficiently removed from the samples. The few HD patients presenting a detectable value in depleted sera (7 of 40) had very high native Oc concentrations (Ͼ200 g/L when measured with ELSA Osteo), which suggested that the anti- 05 by paired t-test) , suggesting that N-terminal mid-Oc had not been captured (even in part) by the anti-43-49 Oc MAb. (c) The percentage of N-terminal mid-Oc, assessed by the ratio: Oc measured by ELSA Osteo in depleted sera/Oc measured by ELSA Osteo in native sera was higher in HD patients than in OP patients (P Ͻ0.05 by unpaired t-test) in accordance with the results previously reported [6] . The evaluated kits showing detectable Oc values in depleted sera were considered as recognizing something else in addition of 1-49 Oc. Table 1 summarizes results obtained with the five evaluated assays. It must be stressed that only two kits (OSCAtest ® and N-tact Osteo ® SP) are clearly said to be exclusively specific for the intact Oc. The specificity of the three other assays is not expressed clearly. The OST KPR kit (CIS bio) is a traditional heterologous RIA directed against bovine Oc (bOc), whereas the two other IRMAs (BGP IRMA and Active Human Osteocalcin TM ) are only said to recognize "human" Oc. In fact, an examination of what we measured in depleted sera (expressed as a percentage of what was measured in native sera-see Table 1 ) suggests that only one of these five kits, the N-tact Osteo SP IRMA kit, recognizes only 1-49 Oc (mean ratio Ͻ2%). What is recognized in depleted sera by the four other assays could be only speculative. According to Garnero et al. [6] , the Oc fragments resulting from tryptic proteolysis that are present in depleted sera may only be 1-43 Oc, 1-19 Oc, and 20 -43 Oc (i.e., fragments that do not contain the C-terminal 44 -49 Oc). However, the exact molecular forms of circulating Oc have never been definitively demonstrated and it cannot be excluded that smaller mid-or N-terminal mid-fragments resulting from other cleavage sites (such as 1-41 Oc resulting from cathepsin D action [11] ) may be present in depleted sera and recognized by the ELSA Osteo kit. As the sandwich methodology needs two distinct epitopes to be present simultaneously, it is unlikely, although not impossible, that the immunoreactivity detected in depleted sera by the two IRMAs (Active and BGP IRMA) may be related to the small 1-19 Oc or 20 -43 Oc. Furthermore, both manufacturers (Mitsubishi and DSL) had found 0% cross-reactivity with synthetic human Oc fragments, namely 1-19 Oc, 12-33 Oc, and 23-33 Oc in the Mitsubishi kit and 1-18 Oc, 20 -33 Oc and 35-49 Oc in the DSL kit. The immunoreactivity detected in depleted sera with these two IRMAs should thus be due to 1-43 Oc or smaller N-terminal mid-fragments. However, the residual immunoreactivity detected with both the DSL and the Mitsubishi kits is proportionally one-third of what is detected with the ELSA Osteo kit. This suggests that N-terminal mid-Oc cross-reacts weakly in these two IRMAs. The specificity of the anti-37-49 Oc polyclonal antibody used in the OSCAtest RIA excludes the possibility that 1-19 Oc may be recognized by this kit. Similarly, the human 1-19 Oc, which differs by five amino acids from its bovine homolog should not be measured by the OST KPR kit. Mid-fragments (20 -43 Oc or smaller) and N-terminal mid-fragments (1-43 Oc or smaller) are thus the best candidates for the immunoreactivity observed in depleted sera with these two RIAs.
In summary, we used a simplification of a method previously described by Garnero et al. [6] to approach the specificity of Oc assays by means of commercially available reagents. This method, which is easily applicable to any Oc assay, allows confirmation of whether a kit claimed as specific for intact Oc exclusively actually has this specificity or not. Oral-facial-digital syndrome II (Mohr syndrome) is an autosomal recessive syndrome characterized by bilateral polysyndactylia of the halluces, bilateral hexadactylia of the hands, lobed tongue, and multiple oral frenula and peculiar facies [1] . Hitherto, no biochemical abnormalities have been associated with this syndrome.
The propositus is a Caucasian boy (mixed Flemish/ German descent) born from an incestuous father-daughter relation. During the pregnancy, a marked intrauterine growth retardation was observed. At delivery, after a pregnancy of 40 weeks, the infant's height (35.0 cm), weight (2400 g), and head circumference (28.2 cm) were all below the first percentile. Diagnosis of Mohr syndrome was confirmed by the observation of polydactylia of the feet; syndactylia of toes 1-2 and 3-4 of both feet; bifid tongue tip with broad, short uvula; bilateral hexadactylia of the hands; and a peculiar facies with micrognathia and microcephaly. Furthermore, the vertebral body T11 was bifurcated and transfontanellar ultrasonography of the brain revealed slightly dilated lateral and third ventricles. Shortly after birth, transient tachypnea and feeding difficulties were present, which gradually disappeared. At the age of 6 weeks, a persistent jaundice was noticed: serum total bilirubin 166 mol/L (reference interval 1-19 mol/L) and conjugated bilirubin 115 mol/L (reference interval 0 -14 mol/L). Stools did not contain bile pigments. Aspartate aminotransferase (AST) (240 U/L, reference interval 16 -58 U/L), alkaline phosphatase (399 U/L, reference interval 225-370 U/L), and ␥-glutamyltransferase (782 U/L, reference interval 11-49 U/L) were increased. l-Alanine aminotransferase (ALT, EC 2.6.1.2) activity (Ͻ1 U/L, reference interval 9 -51 U/L) remained undetectable even after in vitro addition of pyridoxal-5Ј-phosphate (P-5Ј-P) to exclude ALT cofactor deficiency. Total protein (60 g/L) and albumin concentrations (41 g/L) were normal. Serum creatinine was 36 mol/L (reference interval 27-53 mol/L). Inflammatory variables C-reactive protein (14.1 mg/L, reference interval Ͻ5 mg/L) and leukocyte count (20.7 ϫ 10 9 /L, reference interval 7.0 -15.3 ϫ 10 9 /L) were increased. All test results for infectious etiologies were normal. Serological investigations (antibodies against Toxoplasma gondii, Epstein Barr virus, rubella virus, cytomegalovirus, herpes simplex virus, Treponema pallidum, hepatitis B and C viruses, enterovirus, Coxsackie virus) were negative. On ultrasonography the liver was homogeneously dense and not enlarged. Bile ducts were not dilated. Hepatic uptake and excretion of 99-m Tc-imino diacetic acid were both reduced. Cholangiography showed a patent extrahepatic bile tree. At week 7 the patient had to be hospitalized and biochemical variables were determined on admission. One week later, stools became colored under ursodeoxycholic acid therapy (50 mg/day), and cholestasis gradually diminished, but a progressive coagulopathy indicated progression of hepatocellular dysfunction. The prothrombin time was only 6% (reference interval 50 -100%), resulting in an international normalized ratio of 35.3 (reference interval Ͻ2.0). The activated partial thromboplastin time was Ͼ180 s (reference interval 22-37 s). Plasma fibrinogen was 4.22 g/L (reference interval 1.80 -4.55 g/L). On the 11th day of hospitalization, at the age of 10 weeks, the patient died because of a progressive liver failure. A postmortem examination was carried out. All investigations were performed in accordance with the Helsinki declaration of 1975 as revised in 1983.
The pedigree of the propositus (no. 1) is presented in Fig. 1 . The parents are extremely consanguineous (father being maternal grandfather), resulting in an inbreeding coefficient (F) of 0.25 [2] . The patient's brother (no. 2) suffered from a complex congenital heart defect (ventricle septum defect, arteria pulmonalis stenosis, coarctatio aortae) and a sliding-type hernia diaphragmatica. He died at the age of 2 years from septicemia after surgical correction of the congenital defect. Nephew (no. 3), also born from a consanguineous relation, showed similar skeletal malformations and was also diagnosed as having Mohr syndrome. Both the propositus' brother and nephew had normal liver function, and liver enzymes including ALT were within reference limits.
Cytogenetic analysis on phytohemagglutinin-stimulated lymphocytes revealed a normal karyotype.
Serum ALT activity of the propositus' parents and his brother and sisters was within reference limits. At autopsy, liver tissue from the propositus was obtained and an extract was prepared according to Tsung [3] . ALT activity in the liver extract was undetectable (Ͻ1 U/g of wet tissue, reference interval 50 -70 U/g), whereas normal activities of alkaline phosphatase, ␥-glutamyltranspeptidase, and AST were found. ALT activities in serum and liver tissue extract were measured according to the IFCC [4, 5] at 37°C on a Hitachi 747 analyzer with reagents supplied by Boehringer Mannheim. In vitro addition of the ALT coenzyme P-5Ј-P (final concentration: 4.5 mmol/L) [6] did not result in an increase of serum or liver tissue extract ALT activity. Presence of ALT-inhibiting substances in the patient's serum was investigated with a mixing experiment in which the patient's serum was incubated at 37°C for 10 min with an equal amount of pooled serum originating from healthy blood donors. The measured ALT activity of the mixture corresponded to the theoretically expected activity and thus did not reveal the presence of an ALT inhibitor in the patient's serum.
Light microscopy revealed portal tracts with hypoplasia of the interlobar bile ducts and a discrete ductular metaplasia surrounded by biliary fibrosis. In numerous hepatocytes accumulation of bile pigments was present. A Clinical Chemistry 43, No. 9, 1997 pseudoglandular arrangement of the hepatocytes occurred. Electron microscopy of the hepatocytes revealed mitochondria with a condensed matrix and a concomitant expansion of the space between the inner and outer membranes. The endoplasmic reticulum showed dilatation of the saccules. These were filled with a mediumdense protein-containing material. Bile pigments were accumulated in the cytoplasm. Postmortem examination of the liver revealed secondary biliary fibrosis. No morphological alterations were observed at the cerebrum, cerebellum, and hippocampus.
Oral-facial-digital syndrome type II (Mohr syndrome) is a rare malformation syndrome, mainly involving the musculoskeletal system. The musculoskeletal malformations found in the propositus are diagnostic for this syndrome. The presence of two nephews with Mohr syndrome within an extremely consanguineous family is suggestive of an autosomal recessive inheritance of this condition [1, 7] . Neither liver and bile duct abnormalities, nor the absence of ALT activity as observed in the propositus, have been reported to be a part of this syndrome [1, 7] . In the propositus, a hepatocellular dysfunction was present, as evidenced by the increased liver enzyme activities in the serum and the present coagulopathy. In contrast, ALT activity in serum was undetectable. ALT activity is found in many cell types, but the highest activity is found in liver and kidney tissue [5] . ALT plays a role in the transfer of amino groups from alanine to ␣-ketoglutaric acid. This reaction provides a source of nitrogen for the urea cycle [5, 8] . Earlier, Cooper et al. [9, 10] demonstrated in a rat liver model the important role of ALT in homeostasis by its high capacity to shuttle nitrogen as needed. The lack of ALT could interfere with this nitrogen shuttling and also deprive the liver of an energy source. Considering these data, it might not be surprising that liver failure occurred in this patient.
Enzyme deficiencies theoretically can be caused by an absence of enzyme molecules, by the absence of a coenzyme, or by the presence of inhibitors. Absence of the coenzyme P-5Ј-P and its amino analog, pyridoxamine-5Ј-phosphate, and the presence of inhibitors could be excluded in the propositus. Most likely, the propositus had an ALT deficiency due to absence of active enzyme molecules. Earlier, acquired deficiency of ALT was described in hemodialysis patients [11, 12] . In these patients, this deficiency has been partly attributed to a deficiency of the ALT cofactor, P-5Ј-P. Endogeneous inhibitors of ALT have not been described yet. Also, a congenital absence of ALT in serum or tissue has not been reported until now. Thus, primary ALT deficiency is an extremely rare condition.
The isolated finding of ALT deficiency in the propositus suggests that both parents must have been heterozygous for ALT deficiency and therefore points towards an autosomal recessive inheritance. The finding of a nephew with Mohr syndrome but without ALT deficiency suggests that both conditions are unlinked, and that the propositus has inherited Mohr syndrome as a result of the extreme relatedness of the parents. However, the finding of an isolated ALT deficiency in the propositus should not exclude that this ALT deficiency is part of a hitherto undescribed general metabolic disorder or occurs in association with the observed morphological abnormalities in the liver tissue of our patient.
Electron microscopy of the liver showed an endoplasmic reticulum with web-like cannalicular appearance and vesicular dilatation. The changes of the endoplasmic reticulum are suggestive of a defect in protein processing. The mitochondria were characterized by a variable morphology with a tendency to angular widening. In this respect the changes in the mitochondria can be expected to be secondary changes reflecting the condition of the hepatocyte. A marked intrahepatic cholestasis was found, as evidenced by the histological and biochemical analysis (accumulation of bile pigments and increased bilirubin and alkaline phosphatase activity) and nuclear imaging. These morphological findings have not been associated earlier with Mohr syndrome and are hitherto undescribed in the literature. As ALT is mainly a cytosolic enzyme and the morphological changes concern the endoplasmic reticulum and mitchondria, the patient had an undescribed complex congenital syndrome.
In conclusion, we report the first case of a congenital ALT deficiency associated with endoplasmic reticulum and mitochondrial morphological abnormalities in liver tissue in a patient with Mohr syndrome born from an extremely consanguineous relation. HPLC is a sensitive and rapid method for separating and quantifying hemoglobin (Hb) variants [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Accurate quantification of Hb S is an essential component in the discrimination of uncomplicated Hb S trait from other conditions characterized by the presence of Hb S. This is particularly important at our institution where the initial screening of new Air Force recruits for potentially disqualifying hematologic conditions is essential before the inception of basic training activities. The Bio-Rad Variant is an automated cation-exchange HPLC method technically well suited for the rapid and accurate quantification of Hb A 2 and Hb F [8] . Chromatography of each sample is completed in 6 min. The system also resolves and allows presumptive identification of common Hb variants (Hb S and C) [9] . Confirmation of the Hb variants detected by the system must be performed by using an alternative method.
We evaluated the analytical performance of the Bio-Rad Variant HPLC System in the resolution and quantification of Hb S. Reference ranges for Hb S and Hb A 2 were established for individuals with uncomplicated Hb S trait.
Our reference laboratory (Brooks Epidemiology Lab) receives 250 to 300 requests for Hb electrophoresis per month. Referring facilities submit an EDTA-anticoagulated whole-blood specimen and are asked to provide complete blood count (CBC) results, a stained peripheral smear, recent transfusion history, pertinent patient history, ethnic background, age, and serum ferritin results, if available. A Hb electrophoresis panel consisting of a screen for sickle Hb, quantification of Hb fractions (normally Hb A, Hb A 2 , and Hb F), alkaline agarose gel electrophoresis, and acid agarose gel electrophoresis (as required for confirmation of the identity of abnormal Hbs) is performed. Specimens from 319 patients identified as containing Hb S were used to evaluate the analytical performance of the Bio-Rad Variant and establish reference ranges. Clinical specimens were used in accordance with the policies of the Clinical Investigation Division of Wilford Hall Medical Center, Lackland Air Force Base, TX. Of these cases, 174 were diagnosed as uncomplicated S trait. Criteria used for this diagnosis included normal Hb concentration (females Ն120 g/L, males Ն140 g/L), mean cell volume (MCV) Ն84 fL, and Hb A/S phenotype (Hb S Ͻ50% and Ͼ35%). Twenty-two cases were diagnosed as presumptive Hb S-␣ thalassemia traits (Hb S Ͻ35%, MCV Ͻ80%, and normal serum ferritin) and 13 specimens from nine patients with apparent homozygous Hb S were evaluated. Five patients were identified with probable Hb S-␤ ϩ thalassemia and one neonate was identified with probable Hb S-␤ o thalassemia. The remaining cases consisted of Hb S trait with an abnormal Hb concentration or MCV, Hb S trait with iron-deficiency anemia, infants with Hb S trait, or cases for which CBC results were not available.
Sickle screening was accomplished with a commercially prepared solubility test kit, Columbia Calibre Sickle Cell Reagent Set (Columbia Diagnostics).
Hb S in one neonatal sample was confirmed with a monoclonal antibody assay, HemoCard (Isolab).
Alkaline Hb electrophoresis on agarose gel was performed on EDTA-anticoagulated whole-blood samples with the Paragon Hemoglobin Electrophoresis Kit (Beckman Instruments) in the Paragon Accessory System (Beckman). Acid Hb electrophoresis on agarose gel was performed to confirm the identity of the Hbs resolved by alkaline electrophoresis with the Paragon Acid Hemoglobin (Acid Hb) Kit (Beckman). The percentage of each Hb resolved by alkaline electrophoresis was measured by densitometry with the Appraise Densitometer (Beckman).
Quantification of Hb A 2 and Hb F and screening for the presence of Hb variants were accomplished by cationexchange HPLC with the ␤-thalassemia Short Program in the Variant (Bio-Rad Labs.). Hb A and Hb S concentrations were corrected for small unknown peaks (glycosylated Hbs and degradation peaks) with the following formula: Hb S corrected ϭ [100 Ϫ (Hb A 2 ϩ Hb F)][Hb S/(Hb A ϩ Hb S)], where 100 Ϫ (Hb A 2 ϩ Hb F) is the Hb percentage remaining after quantification of Hbs A 2 and F by HPLC, and Hb S/(Hb A ϩ Hb S) is the proportion of the remaining Hb that is Hb S relative to the total of Hb A and Hb S measured by HPLC or alkaline electrophoresis. Hb A corrected may also be calculated by multiplying the relative proportion of Hb A, (Hb A/Hb A ϩ Hb S), times the remaining percentage of Hb [100 Ϫ (Hb A 2 ϩ Hb F)], or, more simply, Hb A corrected ϭ 100 Ϫ (Hb A 2 ϩ Hb F) Ϫ Hb S corrected .
The accuracy of the HPLC method for quantification of Hb S was evaluated by split-sample comparison with Clinical Chemistry 43, No. 9, 1997 
